Tara Graff | University of Iowa Clinical Research and Trials

Attention Site Visitor

You are currently visiting the UI Health Care Clinical Trials website on a version of the web browser: Internet Explorer. Internet Explorer is no longer being supported by Microsoft, and there are features and functionality on this website that does not operate properly when using Internet Explorer. If you have an alternative browser, such as: Microsoft Edge, Google Chrome, Mozilla Firefox, or Apple Safari, we suggest you switch to that browser for the optimal viewing experience.

Thank you

Studies

MISSION: BeiGene, Ltd. / A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Exigent)

Cancer Internal Medicine Leukemia Adult Subjects

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)